Clarity Pharmaceuticals Reports First Patient Dosing in P-I/IIa Study (CL04) of the 64Cu/67Cu Sartate to Treat Neuroblastoma
Shots:
- The company dosed its first patients in cohort 2 of the 64Cu/67Cu Sartate study (CL04) at the increased dose level of 175MBq/kg following the completion of cohort 1 (n=3) with 67Cu Sartate at a dose of 75MBq/kg
- The P-I/IIa dose-escalation study (NCT04023331) is a theranostic (diagnosis and therapy) study (n=34) conducted at five sites in the US in pediatric patients with high-risk neuroblastoma
- In 2020, the company received two RPDDs & ODDs from the US FDA for 64Cu Sartate (as a diagnostic agent & as a therapy of neuroblastoma). The RPDDs allow the company to access the two PRVs which most recently traded at $110M per voucher
Ref: PR Newswire | Image: Clarity
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
